151 related articles for article (PubMed ID: 20851159)
1. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B; Klyuchnikov E; Kröger N; Zabelina T; Stahl T; Zeschke S; Badbaran A; Ayuk F; Alchalby H; Wolschke C; Bokemeyer C; Fehse B; Zander AR; Bacher U
Exp Hematol; 2010 Dec; 38(12):1261-71. PubMed ID: 20851159
[TBL] [Abstract][Full Text] [Related]
2. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
3. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
[TBL] [Abstract][Full Text] [Related]
4. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms.
Jiménez-Velasco A; Barrios M; Román-Gómez J; Navarro G; Buño I; Castillejo JA; Rodríguez AI; García-Gemar G; Torres A; Heiniger AI
Leukemia; 2005 Mar; 19(3):336-43. PubMed ID: 15674363
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
6. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
[TBL] [Abstract][Full Text] [Related]
7. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
[TBL] [Abstract][Full Text] [Related]
8. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
[TBL] [Abstract][Full Text] [Related]
9. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
10. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
11. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats.
Frankel W; Chan A; Corringham RE; Shepherd S; Rearden A; Wang-Rodriguez J
Am J Hematol; 1996 Aug; 52(4):281-7. PubMed ID: 8701946
[TBL] [Abstract][Full Text] [Related]
12. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
13. [Allogenic transplantation of hematopoietic stem cells in the treatment of children with high-risk acute leukemia].
Starý J; Kobylka P; Sedlácek P; Komrska V; Vávra V; Syrůcková Z; Smísek P; Hrubá A; Korínková P; Matĕjková E; Cukrová V; Dolezalová L; Loudová M; Sejkorová J; Kvĕch J
Cas Lek Cesk; 1998 Jun; 137(12):363-7. PubMed ID: 9721472
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.
Sayer HG; Kröger M; Beyer J; Kiehl M; Klein SA; Schaefer-Eckart K; Schwerdtfeger R; Siegert W; Runde V; Theuser C; Martin H; Schetelig J; Beelen DW; Fauser A; Kienast J; Höffken K; Ehninger G; Bornhäuser M;
Bone Marrow Transplant; 2003 Jun; 31(12):1089-95. PubMed ID: 12796788
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
16. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
17. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
18. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
